Oral desensitization in Rh disease.
Four pregnancies managed with erythrocyte membrane oral therapy because of severe Rh disease are presented. Reduction in anti-(D) production was the goal of the study. A patient was classified as having severe Rh immunization if there was a history of fetal loss due to erythroblastosis fetalis prior to 26 weeks.
D000284:Administration, Oral; D000328:Adult; D002214:Capsules; D002462:Cell Membrane / Q000276:immunology; D003888:Desensitization, Immunologic; D004899:Erythroblastosis, Fetal / Q000276:immunology / Q000401:mortality / Q000517:prevention & control*; D004912:Erythrocytes / Q000276:immunology*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D012204:Rh-Hr Blood-Group System / Q000276:immunology*
D002214:Capsules; D012204:Rh-Hr Blood-Group System